NCT03959358View on ClinicalTrials.gov

A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 3, 2020

Primary Completion Date

June 30, 2022

Study Completion Date

October 7, 2022

Conditions
Multiple MyelomaAmyloidosis
Interventions
DRUG

Lenalidomide

Lenalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).

DRUG

Pomalidomide

Pomalidomide is an antineoplastic and immunomodulatory agent that will be given as a liquid in syringes to be taken orally (by mouth).

Trial Locations (1)

M5G 2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT03959358 - A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders | Biotech Hunter | Biotech Hunter